Key result
Percutaneous tricuspid valve implantation is a less invasive, safe, and effective alternative to redo open-heart surgery for patients with severe tricuspid valve bioprosthesis dysfunction.
Why the study?
Bioprosthetic tricuspid valves have limited durability and lead to repeated open-heart surgeries, prompting the need to summarize indications, procedural details, and outcomes for percutaneous tricuspid valve implantation.
Does percutaneous tricuspid valve implantation (PTVI) improve outcomes in patients with severe tricuspid valve dysfunction and failing bioprostheses?
Does percutaneous tricuspid valve implantation (PTVI) improve outcomes in patients with severe tricuspid valve dysfunction and failing bioprostheses?
PTVI is a promising, less invasive alternative to redo open-heart surgery for patients with congenital heart disease and failing tricuspid bioprostheses.
Severe tricuspid valve (TV) dysfunction in patients with congenital heart disease (CHD) is usually treated by open heart surgery in relatively young patients. If a valve plasty is not possible, a biological valve is implanted with a limited durability. Due to valve degeneration repeated valve exchanges are necessary in these patients. To expand the lifetime of a bioprosthesis in tricuspid position percutaneous TV implantation (PTVI) was introduced recently. PTVI is a promising new catheter interventional technology. The current review summarizes the indication for PTVI, describes the procedure itself and gives an outlook on medium to long-term results of this catheter intervention. PTVI in patients with severe TV dysfunction is less invasive, safe and effective, if performed by an experienced operator, and may help to reduce the total number of open-heart surgeries during a patient's life time. However, further studies with larger patient numbers and longer follow-up are needed.
No takes yet. Share an insight, caveat, or question.
Eicken et al. (2018) conducted a review in Severe tricuspid valve dysfunction with failing bioprosthesis. Percutaneous tricuspid valve implantation (PTVI) vs. Open-heart surgery (historical context) was evaluated. Percutaneous tricuspid valve implantation is a less invasive, safe, and effective alternative to redo open-heart surgery for patients with severe tricuspid valve bioprosthesis dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: